ReviewFrontiers in microbiology2024
Antibiotics with antibiofilm activity - rifampicin and beyond.
Review in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Antibiotic Selection for Sustained Local Therapy May Be Important to ReduceMicroorganisms · 2026Article
- Rifampicin in Osteoarticular Infections: A Comprehensive Review of Current Evidence.Antibiotics (Basel, Switzerland) · 2026Review
- Staphylococcus aureus biofilms: molecular mechanisms, resistance determinants, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Strategies to prevent post-operative surgical site infection in spinal surgery: a narrative review.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Review
- Multifunctional Curcumin-Inspired 3,5-Diarylidene-4-Piperidones: Design, Synthesis, Biological Evaluation and Computational Mechanistic Studies.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Repurposing Non-Infectious Therapeutic Agents to Aid in the Treatment of Chronic Biofilm Infections.Medical sciences (Basel, Switzerland) · 2026Review
- Breaking Down Barriers: CorA Effectively Targets Staphylococcal Biofilms in Vitro and in Vivo.ChemMedChem · 2026Article
- Therapeutic Strategies and Clinical Outcomes of Infections Following Anterior Cruciate Ligament Reconstruction: A Narrative Review.Orthopaedic surgery · 2026Review
- EthanolicMicroorganisms · 2026Article
- Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Enzymes-enhanced antibiotic therapy reduces biofilms to undetectable levels in an implant-associated infection model.NPJ biofilms and microbiomes · 2026Article
- Effects of Glutathione on Antibiotic Susceptibility and Resistance in Bacteria: A Comprehensive Review.Infection and drug resistance · 2026Review
- Combination Antibiotic Therapy for Orthopedic Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Outbreak of NDM-5-ProducingAntibiotics (Basel, Switzerland) · 2025Article
- Mechanisms of antibiofilm compounds JG-1 and M4 across multiple species: alterations of protein interactions essential to biofilm formation.Frontiers in cellular and infection microbiology · 2025Article
- Off-label use of intravenous rifampicin during surgery: analysis of Australian surveillance data and retrospective audit at a tertiary hospital.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of prosthetic joint infections is a complex and multilayered process that is additionally complicated by the formation of bacterial biofilm. Foreign material provides the ideal grounds for the development of an intricate matrix that hinders treatment and creates a difficult environment for antibiotics to act. Surgical intervention is often warranted but requires appropriate adjunctive therapy. Despite available guidelines, several aspects of antibiotic therapy with antibiofilm activity lack clear definition. Given the escalating challenges posed by antimicrobial resistance, extended treatment durations, and tolerance issues, it is essential to ensure that antimicrobials with antibiofilm activity are both potent and diverse. Evidence of biofilm-active drugs is highlighted, and alternatives to classical regimens are further discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.